ClinicalTrials.gg
CompletedNCT01311687NIMBUSUpdated Oct 24, 2018Results posted

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

A Phase 3 interventional study of pomalidomide and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 94 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-24.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
455
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
9th of 102
455 · median 50
Started
2011
with 5 others
Phase 3
17 of 102
3 open now
Registered
8th of 102
by date
Lead sponsor
10 of 102
Celgene

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 9th largest by enrollment, is one of 6 that started in 2011, is one of 17 in phase 3, and was the 8th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Myeloma
  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Relapsed and Refractory Multiple Myeloma
  • Refractory Myeloma
  • Resistant Multiple Myeloma
  • Treatment-resistant Multiple Myeloma
  • Pomalidomide
  • Lenalidomide-resistant
  • Bortezomib-resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥ 18 years of age
  • Subjects must have documented diagnosis of multiple myeloma and have
  • Subjects must have undergone prior treatment with ≥ 2 treatment lines of anti-myeloma therapy
  • Subjects must have either or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last myeloma therapy
  • All subjects must have received at least 2 consecutive cycles of prior treatment that included lenalidomide and bortezomib
  • All subjects must have failed treatment with both lenalidomide and bortezomib in one of the following ways: 1) Documented progressive disease on or within 60 days of completing treatment with lenalidomide and/or bortezomib, or 2) In case of prior response [≥ partial response (PR)] to lenalidomide or bortezomib, subjects must have relapsed within 6 months after stopping treatment with lenalidomide and/or bortezomib-containing regimens, or 3) Subjects who have not had a ≥ minimal response (MR) and have developed intolerance/toxicity after a minimum of two cycles of lenalidomide- and/or bortezomib-containing regimen
  • Patients must have received adequate prior alkylator therapy
  • (ECOG) performance status score of 0, 1, or 2
  • Females of (FCBP) must not become pregnant for 28 days prior to initiation of study drug, during the study, and for 28 days after discontinuation
  • Females must agree to abstain from breastfeeding during study participation and 28 days after study drug discontinuation
  • Males must agree to use a latex condom during any sexual during the study and for 28 days following discontinuation from this study
  • Males must also agree to refrain from donating semen or sperm while on pomalidomide and for 28 days after discontinuation from this study

Exclusion criteria

Exclusion Criteria:

  • Any of the following laboratory abnormalities:

    • (ANC) \< 1,000/μL
    • count \< 75,000/ μL for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells
    • \< 45 mL/min
    • Corrected serum calcium > 14 mg/dL
    • ≤ 8 g/dL
    • Serum glutamic oxaloacetic transaminase ()/ aspartate aminotransferase (AST) or transaminase, serum glutamic pyruvic (SGPT)/ alanine aminotransferase (ALT) > 3.0 x (ULN)
    • Serum total > 2.0 mg/dL
  • Previous therapy with pomalidomide
  • to thalidomide, lenalidomide, or dexamethasone
  • Resistance to high-dose dexamethasone used in the last
  • Peripheral neuropathy ≥ Grade 2
  • Subjects who received an allogeneic bone marrow or peripheral blood stem cell transplant
  • Subjects who are planning for or who are eligible for stem cell transplant
  • Subjects with any one of the following: 1) Congestive heart failure, 2) Myocardial infarction within 12 months prior to starting study treatment, 3) Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris
  • Subjects who received any of the following within the last 14 days of initiation of study treatment: 1) Plasmapheresis, 2) Major surgery, 3) Radiation therapy, 4) Use of any anti-myeloma drug therapy
  • Use of any agents within 28 days or 5 half-lives (whichever is longer) of treatment
  • Subjects with conditions requiring chronic or treatment
  • Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
  • Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide
  • Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subjects from signing the form
  • Pregnant or breastfeeding females
  • Known (HIV) positivity or active infectious hepatitis A, B, or C
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
455 participants (actual)

Study arms

  • Experimental
    Pomalidomide + Low-Dose Dexamethasone

    Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.

    Drug: pomalidomide · Drug: Dexamethasone

  • Active comparator
    High-Dose Dexamethasone

    Participants received 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.

    Drug: Dexamethasone

Interventions

  • 4 mg pomalidomide capsules administered orally

    Also known as: CC-4047, Pomalyst®

  • 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) tablets administered orally

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) - Primary Analysis

    Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease required 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

    Time frame: From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.

  2. Progression-free Survival (PFS) With a Later Cut-off Date

    Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.

    Time frame: From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.

  2. Overall Survival - Primary Analysis

    Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

    Time frame: From randomization until the data cut-off date of 07 September 2012. Maximum time on follow-up for survival was 70 weeks.

  3. Overall Survival With a Later Cut-off Date

    Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up for survival was 93 weeks.

  4. Overall Survival Based on the Final Dataset

    Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

    Time frame: From randomization until the data cut-off date of 29 August 2017. Maximum time on follow-up for survival was 324 weeks.

  5. Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria

    Objective response is defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on the Independent Response Adjudication Committee: SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  6. Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria

    Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the Independent Response Adjudication Committee: CR requires all of the following: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  7. Time to Progression

    Time to progression (TTP) is calculated as the time from randomization to the first documented progression confirmed by a blinded, independent Response Adjudication Committee and based on the International Myeloma Working Group Uniform Response criteria (IMWG). Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  8. Time to Response

    Time to response is calculated as the time from randomization to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  9. Duration of Response

    Duration of response (calculated for responders only) is defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria assessed by the Independent Response Adjudication Committee.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  10. Time to the First Hemoglobin Improvement

    Time to increased hemoglobin, defined as the time from randomization to at least one category improvement from Baseline in common terminology criteria for adverse events (CTCAE) grade for hemoglobin level. Hemoglobin categories are: 1) Normal; 2) CTCAE Grade 1: \< lower limit of normal (LLN) to 10.0 g/dL; 3) CTCAE Grade 2: \< 10.0 to \<8.0 g/dL. Participants with CTCAE Grade 3 anemia or worse at Baseline were excluded from the study.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  11. Time to Improvement in Bone Pain

    Time to improvement in bone pain is defined as the time from randomization to at least one category improvement from Baseline in bone pain category. Bone pain was categorized (from best to worst) according to answers to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for patients with Multiple Myeloma Module (QLQ-MY20), Question 1, "Have you had bone aches or pain?": 1) Not at all, 2) A little, 3) Quite a bit, or 4) Very much.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  12. Time to Improvement in Renal Function

    Time to improvement in renal function is defined as the time from randomization to at least one category improvement from Baseline in renal function. Renal Function was categorized as (from best to worst): - Normal: creatinine clearance ≥80 mL/min; - Grade 1: creatinine clearance ≥60 to \<80 mL/min; - Grade 2 : creatinine clearance ≥45 to \< 60 mL/min. Participants with creatinine clearance \< 45 mL/min at baseline were excluded from the study.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  13. Time to Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status

    Time to improvement in ECOG performance status defined as the time from randomization until at least a one category improvement from Baseline in ECOG performance status score. The categories of the ECOG Performance Status Scale are as follows: -0: Fully active, able to carry on all pre-disease performance without restriction; -1: Restricted in physically strenuous activity but ambulatory and able to carry our work of a light or sedentary nature, e.g., light housework, office work; -2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. Patients with a score of 3, 4 or 5 were excluded from participating in the study.

    Time frame: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.

  14. Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  15. Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  16. Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  17. Change From Baseline in the EORTC QLQ-C30 Fatigue Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  18. Change From Baseline in the EORTC QLQ-C30 Pain Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reductions in pain (i.e. improvement in symptom) and positive values indicate increases in pain (i.e. worsening of symptom).

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  19. Change From Baseline in the European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms

    The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Disease Symptoms Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction (i.e. improvement) in symptoms and positive values indicate increase (i.e. worsening) of symptoms.

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  20. Change From Baseline in the EORTC QLQ-MY20 Side Effects Domain

    The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Side Effects Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction in side effects (i.e.improvement in symptom) and positive values indicate increase in side effects (i.e. worsening of symptom).

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  21. Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Utility Index Score

    EQ-5D is a self-administered questionnaire that assesses health-related quality of life (QOL). The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where an EQ-5D score of 1.00 equals "perfect health", a score of 0 equals "death" and a score of -0.59 equals worst imaginable health state. A positive change from Baseline score indicates improvement in health status. A negative change from Baseline score indicates worsening in health status. Negative scores represent the possible though unlikely situation that a patient's QOL is worse than death, i.e. they would rather be dead than living with that QOL

    Time frame: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6

  22. Time to First Worsening of Quality of Life (QOL) Domains

    Time to worsening in quality of life domains was calculated as the time from Baseline to the first worsened minimally important difference (MID), defined as the smallest change in a QOL score considered important to patients that would lead the patient or clinician to consider a change in therapy. MID thresholds were calculated in Standard Error of Measurement (SEM) units using the Baseline QOL data. Based on the MID, participants were classified as worsened according to the following: For the EORTC QLQ-C30 global health status and functional scales and the EQ-5D health utility score, participants were classified as worsened if their change from Baseline score was less than -1 SEM. For the EORTC QLQ-C30 symptom scores (fatigue and pain) and EORTC QLQ-MY20 disease symptoms and side effects scales, participants were classified as worsened if their change from Baseline score was greater than 1 SEM. See previous outcome measures for definitions of each scale.

    Time frame: Assessed on Day 1 of the first 6 treatment cycles.

07

Results

Posted Apr 30, 2014

Participant flow

The study was conducted at 93 sites: 68 sites in Europe, 10 sites in Australia, 10 sites in Canada, 4 sites in Russia, and 1 site in the United States (US) from 18 March 2011 to 29 August 2017.

Treatment Phase
Participant flow — Treatment Phase
MilestonePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone (HD-Dex)
Started302153
Received study drug300150
Crossed-over to pomalidomide011
Completed302153
Not completed00
PFS Follow-up Phase
Participant flow — PFS Follow-up Phase
MilestonePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone (HD-Dex)
Started118
Crossed-over to pomalidomide110
Completed118
Not completed00

Outcome measures

PrimaryProgression-free Survival (PFS) - Primary Analysis

Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease required 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

Time frame:
From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.
Reported as:
Median · weeks
Progression-free Survival (PFS) - Primary Analysis
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Progression-free Survival (PFS) - Primary Analysis15.7 (13.0 to 20.1)8.0 (7.0 to 9.0)
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Stratified Log Rank Test · p = <0.001 · Hazard ratio (hr): 0.45 · 95% CI 0.35 to 0.59Hazard ratio is for Pomalidomide Plus Low-Dose Dexamethasone : High Dose Dexamethasone
PrimaryProgression-free Survival (PFS) With a Later Cut-off Date

Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.
Reported as:
Median · weeks
Progression-free Survival (PFS) With a Later Cut-off Date
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Progression-free Survival (PFS) With a Later Cut-off Date16.0 (13.0 to 19.6)8.1 (7.1 to 9.4)
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Stratified log-rank test · p = <0.001 · Hazard ratio (hr): 0.49 · 95% CI 0.39 to 0.61Hazard ratio is for Pomalidomide Plus Low-Dose Dexamethasone : High Dose Dexamethasone
SecondaryNumber of Participants With Adverse Events (AEs)

An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.

Time frame:
From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneHD-Dex / Pomalidomide
Any adverse event29814911
Grade 3-4 adverse events2661278
AE related to pomalidomide251011
AE related to dexamethasone2051155
AE related to either study drug27111511
Grade 3-4 AE related to pomalidomide19906
Grade 3-4 AE related to dexamethasone114702
Grade 3-4 AE related to either study drug212706
Grade 5 adverse events46211
Serious adverse events (SAEs)195804
SAE related to pomalidomide8901
SAE related to dexamethasone73360
SAE related to either study drug98361
SAE leading to discontinuation of pomalidomide2001
SAE leading to discontinuation of dexamethasone20141
SAE leading to discontinuation of either study dru23141
AE leading to discontinuation of pomalidomide3001
AE leading to discontinuation of dexamethasone34161
AE leading to discontinuation of either study drug38161
SecondaryOverall Survival - Primary Analysis

Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Time frame:
From randomization until the data cut-off date of 07 September 2012. Maximum time on follow-up for survival was 70 weeks.
Reported as:
Median · weeks
Overall Survival - Primary Analysis
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Overall Survival - Primary AnalysisNA (48.1 to NA)34.0 (23.4 to 39.9)
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Log Rank · p = <0.001 · Hazard ratio (hr): 0.53 · 95% CI 0.37 to 0.74Hazard ratio is for Pomalidomide Plus Low-Dose Dexamethasone : High Dose Dexamethasone
SecondaryOverall Survival With a Later Cut-off Date

Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up for survival was 93 weeks.
Reported as:
Median · weeks
Overall Survival With a Later Cut-off Date
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Overall Survival With a Later Cut-off Date54.0 (45.3 to 66.4)34.9 (29.9 to 39.1)
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Log Rank · p = 0.009 · Hazard ratio (hr): 0.70 · 95% CI 0.54 to 0.92Hazard ratio is for Pomalidomide Plus Low-Dose Dexamethasone : High Dose Dexamethasone
SecondaryOverall Survival Based on the Final Dataset

Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Time frame:
From randomization until the data cut-off date of 29 August 2017. Maximum time on follow-up for survival was 324 weeks.
Reported as:
Median · weeks
Overall Survival Based on the Final Dataset
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Overall Survival Based on the Final Dataset56.1 (47.7 to 67.4)35.3 (29.9 to 39.9)
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Log Rank · p = 0.005 · Hazard ratio (hr): 0.74 · 95% CI 0.60 to 0.91Hazard ratio is for Pomalidomide Plus Low-Dose Dexamethasone : High Dose Dexamethasone
SecondaryPercentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria

Objective response is defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on the Independent Response Adjudication Committee: SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria
percentage of participantsPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria23.53.9
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Fisher Exact · p = < 0.001 · Odds ratio (or): 7.53 · 95% CI 3.19 to 17.77Odds ratio is for pomalidomide plus low-dose dexamethasone : high dose dexamethasone
SecondaryPercentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria

Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the Independent Response Adjudication Committee: CR requires all of the following: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria
percentage of participantsPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria22.23.3
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Fisher Exact · p = < 0.001 · Odds ratio (or): 8.44 · 95% CI 3.32 to 21.42Odds ratio is for Pomalidomide Plus Low-Dose Dexamethasone : High Dose Dexamethasone
SecondaryTime to Progression

Time to progression (TTP) is calculated as the time from randomization to the first documented progression confirmed by a blinded, independent Response Adjudication Committee and based on the International Myeloma Working Group Uniform Response criteria (IMWG). Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Median · weeks
Time to Progression
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Time to Progression20.0 (16.1 to 24.0)9.0 (8.0 to 10.9)
Statistical analysis
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone · Stratified Log Rank Test · p = < 0.001 · Hazard ratio (hr): 0.46 · 95% CI 0.36 to 0.59Hazard ratio is for Pomalidomide Plus Low-Dose Dexamethasone : High Dose Dexamethasone
SecondaryTime to Response

Time to response is calculated as the time from randomization to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Median · weeks
Time to Response
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Time to Response8.1 (4.0 to 48.0)10.5 (4.1 to 42.1)
SecondaryDuration of Response

Duration of response (calculated for responders only) is defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria assessed by the Independent Response Adjudication Committee.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Median · weeks
Duration of Response
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Duration of Response35.1 (28.4 to 52.9)28.1 (20.1 to 37.1)
SecondaryTime to the First Hemoglobin Improvement

Time to increased hemoglobin, defined as the time from randomization to at least one category improvement from Baseline in common terminology criteria for adverse events (CTCAE) grade for hemoglobin level. Hemoglobin categories are: 1) Normal; 2) CTCAE Grade 1: \< lower limit of normal (LLN) to 10.0 g/dL; 3) CTCAE Grade 2: \< 10.0 to \<8.0 g/dL. Participants with CTCAE Grade 3 anemia or worse at Baseline were excluded from the study.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Median · weeks
Time to the First Hemoglobin Improvement
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Time to the First Hemoglobin Improvement3.4 (1.1 to 49.3)1.3 (0.9 to 24.3)
SecondaryTime to Improvement in Bone Pain

Time to improvement in bone pain is defined as the time from randomization to at least one category improvement from Baseline in bone pain category. Bone pain was categorized (from best to worst) according to answers to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for patients with Multiple Myeloma Module (QLQ-MY20), Question 1, "Have you had bone aches or pain?": 1) Not at all, 2) A little, 3) Quite a bit, or 4) Very much.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Median · weeks
Time to Improvement in Bone Pain
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Time to Improvement in Bone Pain5.7 (3.7 to 88.6)4.1 (3.7 to 27.3)
SecondaryTime to Improvement in Renal Function

Time to improvement in renal function is defined as the time from randomization to at least one category improvement from Baseline in renal function. Renal Function was categorized as (from best to worst): - Normal: creatinine clearance ≥80 mL/min; - Grade 1: creatinine clearance ≥60 to \<80 mL/min; - Grade 2 : creatinine clearance ≥45 to \< 60 mL/min. Participants with creatinine clearance \< 45 mL/min at baseline were excluded from the study.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Median · weeks
Time to Improvement in Renal Function
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Time to Improvement in Renal Function4.6 (3.3 to 45.6)4.1 (3.3 to 28.1)
SecondaryTime to Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status

Time to improvement in ECOG performance status defined as the time from randomization until at least a one category improvement from Baseline in ECOG performance status score. The categories of the ECOG Performance Status Scale are as follows: -0: Fully active, able to carry on all pre-disease performance without restriction; -1: Restricted in physically strenuous activity but ambulatory and able to carry our work of a light or sedentary nature, e.g., light housework, office work; -2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. Patients with a score of 3, 4 or 5 were excluded from participating in the study.

Time frame:
From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
Reported as:
Median · weeks
Time to Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status
weeksPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Time to Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status8.1 (4.1 to 44.1)4.3 (4.1 to 33.7)
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 10.52 ± 23.01-3.75 ± 24.10
Cycle 3, Day 12.67 ± 24.97-2.36 ± 21.08
Cycle 4, Day 10.80 ± 24.62-3.03 ± 22.42
Cycle 5 Day 10.51 ± 26.810.00 ± 27.44
Cycle 6, Day 1-2.51 ± 25.57-0.93 ± 17.59
SecondaryChange From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 1-2.32 ± 18.25-3.96 ± 18.35
Cycle 3, Day 1-0.56 ± 19.86-9.69 ± 16.67
Cycle 4, Day 10.17 ± 20.25-8.08 ± 13.31
Cycle 5 Day 10.91 ± 19.92-5.43 ± 19.31
Cycle 6, Day 10.54 ± 21.30-4.81 ± 14.24
SecondaryChange From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 11.22 ± 21.44-2.87 ± 21.57
Cycle 3, Day 12.40 ± 20.36-5.66 ± 25.36
Cycle 4, Day 12.44 ± 21.05-6.31 ± 23.48
Cycle 5 Day 11.91 ± 21.97-8.64 ± 23.17
Cycle 6, Day 10.19 ± 22.30-4.17 ± 13.18
SecondaryChange From Baseline in the EORTC QLQ-C30 Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Fatigue Domain
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 12.43 ± 27.394.03 ± 25.37
Cycle 3, Day 13.26 ± 27.667.76 ± 23.73
Cycle 4, Day 11.71 ± 26.219.43 ± 28.88
Cycle 5 Day 10.21 ± 28.419.47 ± 23.00
Cycle 6, Day 10.99 ± 31.1310.49 ± 16.38
SecondaryChange From Baseline in the EORTC QLQ-C30 Pain Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reductions in pain (i.e. improvement in symptom) and positive values indicate increases in pain (i.e. worsening of symptom).

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Pain Domain
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 1-2.70 ± 25.740.36 ± 25.32
Cycle 3, Day 1-3.58 ± 29.622.83 ± 25.47
Cycle 4, Day 1-2.41 ± 30.523.03 ± 25.84
Cycle 5 Day 1-1.64 ± 28.002.47 ± 31.59
Cycle 6, Day 1-2.40 ± 30.9910.19 ± 23.67
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms

The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Disease Symptoms Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction (i.e. improvement) in symptoms and positive values indicate increase (i.e. worsening) of symptoms.

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 1-0.50 ± 16.51-1.07 ± 17.78
Cycle 3, Day 1-1.36 ± 19.510.97 ± 19.93
Cycle 4, Day 1-1.15 ± 19.541.35 ± 16.94
Cycle 5 Day 1-0.53 ± 17.391.48 ± 17.56
Cycle 6, Day 10.60 ± 19.642.12 ± 13.43
SecondaryChange From Baseline in the EORTC QLQ-MY20 Side Effects Domain

The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Side Effects Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction in side effects (i.e.improvement in symptom) and positive values indicate increase in side effects (i.e. worsening of symptom).

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-MY20 Side Effects Domain
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 12.71 ± 13.902.61 ± 13.34
Cycle 3, Day 13.26 ± 13.725.35 ± 12.27
Cycle 4, Day 13.73 ± 14.477.46 ± 11.61
Cycle 5 Day 14.74 ± 14.456.89 ± 10.32
Cycle 6, Day 14.55 ± 15.767.30 ± 9.35
SecondaryChange From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Utility Index Score

EQ-5D is a self-administered questionnaire that assesses health-related quality of life (QOL). The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where an EQ-5D score of 1.00 equals "perfect health", a score of 0 equals "death" and a score of -0.59 equals worst imaginable health state. A positive change from Baseline score indicates improvement in health status. A negative change from Baseline score indicates worsening in health status. Negative scores represent the possible though unlikely situation that a patient's QOL is worse than death, i.e. they would rather be dead than living with that QOL

Time frame:
Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Mean · units on a scale
Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Utility Index Score
units on a scalePomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Cycle 2, Day 1-0.03 ± 0.28-0.02 ± 0.23
Cycle 3, Day 10.01 ± 0.29-0.06 ± 0.27
Cycle 4, Day 10.04 ± 0.31-0.07 ± 0.29
Cycle 5, Day 10.01 ± 0.32-0.04 ± 0.26
Cycle 6, Day 10.03 ± 0.31-0.12 ± 0.19
SecondaryTime to First Worsening of Quality of Life (QOL) Domains

Time to worsening in quality of life domains was calculated as the time from Baseline to the first worsened minimally important difference (MID), defined as the smallest change in a QOL score considered important to patients that would lead the patient or clinician to consider a change in therapy. MID thresholds were calculated in Standard Error of Measurement (SEM) units using the Baseline QOL data. Based on the MID, participants were classified as worsened according to the following: For the EORTC QLQ-C30 global health status and functional scales and the EQ-5D health utility score, participants were classified as worsened if their change from Baseline score was less than -1 SEM. For the EORTC QLQ-C30 symptom scores (fatigue and pain) and EORTC QLQ-MY20 disease symptoms and side effects scales, participants were classified as worsened if their change from Baseline score was greater than 1 SEM. See previous outcome measures for definitions of each scale.

Time frame:
Assessed on Day 1 of the first 6 treatment cycles.
Reported as:
Median · days
Time to First Worsening of Quality of Life (QOL) Domains
daysPomalidomide Plus Low-Dose DexamethasoneHigh-Dose Dexamethasone
Global Health Status71 (60 to 92)57 (36 to 91)
Physical Functioning128 (92 to 225)67 (57 to 106)
Emotional Functioning146 (120 to 259)85 (57 to 124)
Fatigue58 (57 to 85)57 (46 to 67)
Pain92 (86 to 147)85 (62 to 337)
Disease Symptoms127 (92 to 155)106 (67 to 141)
Side Effects of Treatment90 (78 to 123)85 (58 to 113)
Health Utility225 (123 to 338)162 (85 to NA)

Adverse events

Collected over From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pomalidomide Plus Low-Dose Dexamethasone252/300 (84%)195/300 (65%)291/300 (97%)
High-Dose Dexamethasone124/150 (82.7%)80/150 (53.3%)143/150 (95.3%)
HD-Dex / Pomalidomide8/11 (72.7%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 234
Most frequent serious events
EventPomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneHD-Dex / Pomalidomide
PneumoniaInfections and infestations57/30014/1502/11
Cardiac arrestCardiac disorders1/3001/1501/11
CellulitisInfections and infestations2/3000/1501/11
Lower respiratory tract infectionInfections and infestations6/3004/1501/11
Pneumonia respiratory syncytial viralInfections and infestations0/3000/1501/11
Respiratory tract infectionInfections and infestations4/3000/1501/11
SyncopeNervous system disorders2/3000/1501/11
Acute kidney injuryRenal and urinary disorders11/3007/1501/11
General physical health deteriorationGeneral disorders26/30012/1500/11
PyrexiaGeneral disorders26/3007/1500/11
Most frequent other events
Showing 10 of 108
Most frequent other events
EventPomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneHD-Dex / Pomalidomide
AnaemiaBlood and lymphatic system disorders159/30077/1504/11
NeutropeniaBlood and lymphatic system disorders155/30030/1505/11
FatigueGeneral disorders103/30040/1503/11
ThrombocytopeniaBlood and lymphatic system disorders87/30042/1501/11
DiarrhoeaGastrointestinal disorders73/30026/1503/11
NauseaGastrointestinal disorders57/30016/1503/11
Oedema peripheralGeneral disorders51/30015/1503/11
PyrexiaGeneral disorders74/30031/1503/11
Decreased appetiteMetabolism and nutrition disorders40/30010/1503/11
ConstipationGastrointestinal disorders72/30022/1501/11

Baseline characteristics

Intent-to-treat population (all participants who were randomized, regardless of whether they received study treatment or not)

Age, Continuous
Age, Continuous(years)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
Mean63.6 ± 9.3363.7 ± 9.5663.6 ± 9.40
Age, Customized
Age, Customized(Participants)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
≤ 75 Years Old278141419
> 75 Years Old241236
Sex: Female, Male
Sex: Female, Male(Participants)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
Female12166187
Male18187268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
Hispanic or Latino271441
Not Hispanic or Latino228104332
Unknown or Not Reported473582
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
Asian404
Black or African American437
White244113357
Other224
Not collected483583
Participants with Prior Anti-Myeloma (MM) Therapies
Participants with Prior Anti-Myeloma (MM) Therapies(Participants)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
Count of participants302153455
Time from First Pathologic Diagnosis
Time from First Pathologic Diagnosis(years)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
Mean6.2 ± 4.026.5 ± 3.636.3 ± 3.89
Stratification Factor 2: Disease Population
Stratification Factor 2: Disease Population(Participants)Pomalidomide Plus Low-Dose DexamethasoneHigh-Dose DexamethasoneTotal
Disease Population Group 1249125374
Disease Population Group 28513
Disease Population Group 3452368

2 further baseline measures are reported on the registry.

08

Study locations

94 sites
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Peter MacCallum Cancer Institute
    East Melbourne, Victoria 3002, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Princess Alexandra Hospital
    Brisbane, QLD4102, Australia
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • Alfred hospital
    Melbourne, 3004, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • Calvary Mater Hospital
    Waratah, NSW 2298, Australia
  • Border Medical Oncology
    Wodonga, 3690, Australia
  • Wollongong Hospital
    Wollongong, 2500, Australia
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU UCL Mont-Godinne-Dinant asbl
    Yvoir, B-5530, Belgium
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • James Cancer Hospital
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Health Sciences Centre
    London, Ontario N6C 6B5, Canada
  • University Health Network
    Toronto, Ontario M5G 2M9, Canada
  • Maisonneuve Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Royal Victoria Hospital McGill Department of Oncology(RVH)
    Montreal, Quebec H3A 1A1, Canada
  • Sir Mortimer B. Davis - Jewish Genl
    Montreal, Quebec H3T 1E2, Canada
  • Charles University General Hospital
    Praha 2, 128 08, Czechia
  • Hæmatologisk afd. B Aalborg Sygehus Syd
    Aalborg, 9000, Denmark
  • Aarhus University Hospital
    Arhus C, DK-8000, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Vejle Hospital
    Vejle, 7100, Denmark
  • CHU d'Angers
    Angers Cedex 01, 49033, France
  • Centre Hospitalier de la cote basque
    Bayonne, 64109, France
  • Centre Hospitalier Departemental
    La Roche sur Yon, 85025, France
  • CHRU de Lille FR
    Lille, 59037, France
  • Institut Paoli-Calmettes
    Marseille Cedex 9, 13009, France
  • CHRU Nantes
    Nantes Cedex 1, 44093, France
  • Hopital Saint-Louis
    Paris, Cedex 10, 75475, France
  • CHU Hôpital St-Antoine
    Paris, 75571, France
  • CHRU - Hopital du Haut Leveque
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite, 69310, France
  • Hopital Bretonneau
    Tours, 37044, France
  • Hopital Purpan
    Tulouse Cedex 9, 31059, France
  • CHU Nancy
    Vandoeuvre, 54511, France
  • Universitatsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • Askepios Klinik St. Georg
    Hamburg, 20099, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitatsklinikum Jena
    Jena, 07740, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • University of Tubingen
    Tübingen, 72076, Germany
  • Universitatsklinikum Ulm
    Ulm, 89081, Germany
  • Universitatsklinikum Wurzburg
    Wuerzburg, 97080, Germany
  • Alexandra General Hospital of Athens
    Athens, 11528, Greece
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • Clinica Ematologica- A.O.U. San Martino
    Genova, 16132, Italy
  • Oncoematologia, Istituto Nazionale Tumori Fondazione G. Pascale
    Napoli, 80131, Italy
  • AOU San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Universita degli Studi di Padova
    Padova, 35128, Italy
  • Hospital Clinic
    Placenza, 29100, Italy
  • Servizio di Ematologia, A.O. - Arcispedale S.Maria Nuova
    Reggio Emilia, 42100, Italy
  • Univerita La Sapienza Dipartimento di Biotecnologie Cellulari ed Ematologia
    Rome, 00161, Italy
  • Azienda Ospedaliera San Giovanni Battista
    Torino, 10126, Italy
  • VU University Medical Center
    Amsterdam, 1081 HV, Netherlands
  • Erasmus Medical Center
    Rotterdam, 3015 CE, Netherlands
  • University Medical Center Utrecht
    Utrecht, 3584 CX, Netherlands
  • State Institution Hematological Research, Centre of Russian Academy of Medical Science
    Moscow, 125167, Russian Federation
  • State Institution Moscow Regional Research Clinical Institute
    Moscow, 125284, Russian Federation
  • State Educational Institution, Saint Petersburg State Medical University
    Saint Petersburg, 197022, Russian Federation
  • St. Petersburg Research Institute of Hematology and Blood Transfusion
    St. Petersburg, 191024, Russian Federation
  • Hospital Universitari Germans Trias i Pujol
    Badalona (Barcelona), 08916, Spain
  • Hospital Clinic Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital de La Princesa
    Madrid, 28006, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Donostia
    San Sebastián (Guipuzcoa), 20014, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital de la Fe
    Valencia, 46009, Spain
  • Department of Hematology Hematology Centre
    Göteborg, S-413 45, Sweden
  • University Hospital in Lund
    Lund, 221 85, Sweden
  • Karolinska University Hospital Huddinge
    Stockholm, SE 17176, Sweden
  • Karolinska University Hospital
    Stockholm, SE-171 76, Sweden
  • Overlakare Medocomcentrum, hematologi
    Uppsala, 75185, Sweden
  • Medizinische Universitatsklinik
    Berne, CH - 3010, Switzerland
  • Hopitaux Universitaires de Geneve-HUG
    Geneva, 1205, Switzerland
  • UniversitatSspital Zurich
    Zürich, 8091, Switzerland
  • Royal Bournemouth Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • St.Bartholomew's Hospital
    London, EC1A 7BE, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • Freeman Hospital
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Nottingham City Hospital
    Nottingham, NG5 1PB, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
  • Royal Hallamshire HospitalSheffield Teaching Hospitals NHS Trust
    Sheffield, S10 2JF, United Kingdom
  • The Royal Marsden Hospital
    Sutton-Surrey, SM2 5PT, United Kingdom
  • The Royal Wolverhampton Hospital NHS Trust
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Publications

  • Moreau P, Weisel KC, Song KW, Gibson CJ, Saunders O, Sternas LA, Hong K, Zaki MH, Dimopoulos MA. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leuk Lymphoma. 2016 Dec;57(12):2839-2847. doi: 10.1080/10428194.2016.1180685. Epub 2016 May 13. PubMed 27173785 ↗
  • Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3. PubMed 24007748 ↗
  • Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016 Dec;57(12):2833-2838. doi: 10.1080/10428194.2016.1177181. Epub 2016 Jun 7. PubMed 27267105 ↗
  • Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Knop S, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel J. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016 Jul;101(7):872-8. doi: 10.3324/haematol.2015.137083. Epub 2016 Apr 14. PubMed 27081177 ↗
  • Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015 Oct;100(10):1327-33. doi: 10.3324/haematol.2014.117077. Epub 2015 Aug 6. PubMed 26250580 ↗
  • San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015 Oct;100(10):1334-9. doi: 10.3324/haematol.2015.125864. Epub 2015 Jul 9. PubMed 26160879 ↗
  • Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):519-30. doi: 10.1016/j.clml.2015.05.007. Epub 2015 Jun 6. PubMed 26149712 ↗
  • Song KW, Dimopoulos MA, Weisel KC, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Monzini MS, Zaki M, Jacques C, San Miguel J. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica. 2015 Feb;100(2):e63-7. doi: 10.3324/haematol.2014.112557. Epub 2014 Nov 25. No abstract available. PubMed 25425684 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Mar 2013, 23 months.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 23 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2011
First posted
Mar 9, 2011
StartActual
Mar 11, 2011
Primary completionActual
Mar 1, 2013
CompletionActual
Aug 29, 2017
Results first posted
Apr 30, 2014
Last update
Oct 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01311687
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Mar 9, 2011
Start date
Mar 11, 2011
Primary completion
Mar 1, 2013
Completion
Aug 29, 2017
Results posted
Apr 30, 2014
Last update
Oct 24, 2018

Study contacts

Lars Sternas, MD, PhD
study director · Celgene

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion